Sign in

You're signed outSign in or to get full access.

Veronica Clark

Research Analyst at Citi

Veronica Clark is an Economist on the US Economics team at Citi, specializing in US economic data, forecasting, and Canadian economics. She provides analysis on macroeconomic indicators, Federal Reserve policy, inflation trends, labor market dynamics, and growth forecasts, with frequent media appearances on CNBC discussing rate cuts and economic vulnerabilities. Clark first joined Citi Research in 2015, initially working in Emerging Markets Strategy and G10 Short Term Interest Rate Trading before transitioning to her current role on the US Economics team. No specific professional credentials such as FINRA registrations or performance metrics like success rates or rankings are publicly detailed in available sources.

Veronica Clark's questions to Fresenius Medical Care (FMS) leadership

Question · Q4 2025

Veronica Clark sought clarification on the EUR 220 million phosphate binder contribution in 2025 and expectations for its unwinding in 2026 and 2027. She also asked for elaboration on the antimicrobial catheter benefit being year-over-year neutral and the company's outlook on ACA subsidy headwinds for 2027 and 2028.

Answer

CFO Martin Fischer confirmed regulatory headwinds of EUR 150-200 million for 2026, including ACA (EUR 50 million) and phosphate binders. He stated that of the EUR 220 million binder contribution in 2025, EUR 100 million is expected to remain in 2026, leading to a significant reduction. Mr. Fischer clarified that the antimicrobial catheter solution will have no year-over-year effect in 2026. CEO Helen Giza added that the TDAPA period ends in 2026, with payments moving into the bundle, and pricing erosion is expected. She emphasized the underlying operational performance, targeting low teens CAGR excluding binder noise.

Ask follow-up questions

Fintool

Fintool can predict Fresenius Medical Care logo FMS's earnings beat/miss a week before the call

Question · Q4 2025

Veronica Clark sought clarification on the phosphate binder contribution of EUR 220 million in 2025 and the expectations for its unwinding in 2026 and 2027. She also asked for elaboration on the year-over-year neutral effect of the antimicrobial catheter benefit and the expected shape of ACA subsidy headwinds in 2027 and 2028.

Answer

CFO Martin Fischer confirmed the EUR 220 million phosphate binder contribution in 2025, noting a reduction of over EUR 100 million in 2026, with EUR 100 million staying in clinics and pharmacy. He clarified that the antimicrobial catheter solution has a neutral year-over-year effect due to its TDAPA period. CEO Helen Giza added that the TDAPA period for the catheter solution ends in 2026, with future payments going into the bundle, and the company is monitoring how branded pricing erodes.

Ask follow-up questions

Fintool

Fintool can write a report on Fresenius Medical Care logo FMS's next earnings in your company's style and formatting